Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lanthanum carbonate Granule Formulation · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Lanthanum carbonate granules | EXPERIMENTAL | Lanthanum carbonate granulated formulation crossover to chewable tablet formulation |
| Lanthanum carbonate chewable tablets (Fosrenol) | EXPERIMENTAL | Lanthanum carbonate chewable table formulation crossover to granulated formulation |
| Name | Type | Description |
|---|---|---|
| Lanthanum carbonate Granule Formulation | DRUG | 3x's per day for 3 days, 1 dose in the am for day 4. (A single dose equals 1000mg of lanthanum carbonate granule formulation. Dose is administered immediately after each meal.) |
| Lanthanum carbonate Chewable Tablets (Fosrenol) | DRUG | 3x's per day for 3 days, 1 dose on day 4. (A single dose equals a 1000mg tablet of lanthanum carbonate. Dose is administered immediately after each meal.) |
Inclusion Criteria * Ability to provide informed consent to participate in the study. * Healthy volunteers, age 18-55 inclusive. * Subject must be willing to comply with applicable contraceptive requirements of the protocol * Female subjects must have a negative pregnancy test * Ability to chew and...
Lanthanum carbonate Granule Formulation is an investigational small molecule being studied for use in End Stage Renal Disease. It is a granule formulation of lanthanum carbonate, a phosphate binder. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Lanthanum carbonate Granule Formulation is a phosphate binder. It works by binding to phosphate in the gastrointestinal tract, reducing its absorption. This mechanism is relevant for patients with End Stage Renal Disease who often have elevated phosphate levels. The drug is being developed as a granule formulation for this purpose.
Lanthanum carbonate Granule Formulation is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company is conducting clinical research on this drug for the treatment of End Stage Renal Disease. The drug is currently in Phase 1 clinical trials.
Lanthanum carbonate Granule Formulation is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied for use in End Stage Renal Disease, and its clinical development is at an early stage.
Lanthanum carbonate Granule Formulation has one completed clinical trial, NCT00880750, titled "Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults." This Phase 1 study enrolled 72 participants in the United States and was a controlled, randomized trial. The study involved healthy volunteers aged 18 years and older.
Lanthanum carbonate Granule Formulation is a specific granule formulation of lanthanum carbonate, the active pharmaceutical ingredient. While lanthanum carbonate itself is a known phosphate binder, this granule formulation is being studied as a distinct drug product. It is currently in Phase 1 clinical trials for End Stage Renal Disease.